Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from MindMed

Can LSD Treat Anxiety? MindMed's New Topline Data Show Promise, Here's The Research

MindMed (NASDAQ: MNMD) researchers shared topline clinical results for a Phase 2 LSD clinical study at the recent Psych Symposium, which was co-sponsored by University Hospital Basel (UHB).

Benzinga

Pro-Patient Psychedelic Treatments Are Finally Moving Forward In A 'New Paradigm Shift'

Last week, Benzinga’s Psychedelics Capital Conference brought a premier gathering of the biggest publicly traded psychedelics companies in North America with forward-thinking investors to Miami, where the hottest topic seemed to revolve around LSD and derivative molecules.

Benzinga

These 3 Psychedelic Stocks Will Benefit When The FDA Green-Lights MDMA (Molly, Ecstasy)

What Happened: According to the Multidisciplinary Association of Psychedelic Studies (MAPS), a non-profit organization, the FDA is close to greenlighting MDMA as a treatment for PTSD. MAPS reported positive results from a phase-3 trial testing the efficacy of MDMA-assisted therapy.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More!

It’s earnings week in the psychedelics space, opening a new window into the financial situations of many companies in the sector.

Benzinga

MindMed Appoints Francois Lilienthal As New CCO

With over twenty years of experience in the biopharmaceutical industry, Francois Lilienthal, MD, has joined Mind Medicine Inc. (NASDAQ:MNMD) as chief commercial officer (CCO). He had been serving as a consultant for the company for the last six months. Lilienthal has a long trajectory with pharmaceutical companies—in 1997, he was…

Benzinga

From Pharma To Psychedelics, Robert Barrow, CEO Of MindMed: Meet Our Speakers

With over ten years of experience in the pharmaceutical industry, Robert Barrow, CEO of Mind Medicine Inc. (NASDAQ:MNMD) is someone who certainly knows the ins and outs of the business. Barrow joined MindMed in January 2021 as Chief Development Officer (CDO) but was later appointed as CEO and member of…

Benzinga

Psyched: Third Michigan City Decriminalizes Psychedelics, MindMed Reports $133M Cash Position, Real Brands To Enter The Space

The psychedelics legislative landscape continues to move forward with Hazel Park, Michigan enacting decriminalization measures for naturally-produced psychedelic molecules, becoming the third city in the state to do so after Ann Arbor and Detroit. In Utah, Governor Cox signed a psychedelics research bill into law and positive legislation around psilocybin is continuing…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

MindMed Reports Full Year 2021 Financial Results, Announces Changes In Leadership

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED) reported its financial results for the full year ended December 31, 2021. 2021 Financial Results Cash balance as of December 31, 2021, was $133.5 million compared to $80.1 million as of December 31, 2020. Net cash in operating activities was $45.8 million for…

Benzinga

Five Companies Developing Second Generation Psychedelics For Mental Health

Along with the psychedelic renaissance came a new type of drug: second generation psychedelics. Developed from classic psychedelics molecules, these upgraded compounds could offer improved therapeutic profiles with reduced side effects. For some companies in the psychedelics space, second generation psychedelics could be the key to success in an increasingly…

Benzinga

Psyched: MindCure Shuts Down Operations, Novamind And MindMed Partner For Study

The psychedelics space was shaken up on the news that MindCure Health (OTC:MCURF) was shutting down operations. After a review process, the company’s board decided that MindCure’s business plan required more capital that it could gather under current market conditions, thus shutting down operations was considered the best move to preserve…

Benzinga

Novamind To Host MindMed Phase IIb Trial For LSD Based Drug For Anxiety Treatment

Novamind Inc. (OTCQB:NVMDF) (CSE:NM) (FSE:HN2) has been selected by Mind Medicine, Inc. (NASDAQ:MNMD) (NEO:MMED) to host a Phase IIb randomized clinical trial investigating lysergic acid diethylamide (LSD) for generalized anxiety disorder in adults.

Benzinga

LSD And Magic Mushroom's Active Compound Appear To Have The Same Effects, New Study Finds

A new peer-reviewed study compared the effects of LSD and psilocybin, two substances currently standing as top molecules behind the recent psychedelic medicine boom. While both compounds have a rich history of human use, not much research has been dedicated to contrasting the effects they produce in human psychology. The…

Benzinga

MindMed Converts Shares To Have A Single Class

Psychedelics-focused biopharma company Mind Medicine Inc. (NASDAQ: MNMD), (NEO:MMED), (DE:MMQ) confirmed Wednesday that all the company’s issued and outstanding multiple voting shares will undergo a mandatory conversion into subordinate voting shares in accordance with the company&rsq

Benzinga

Cybin, MindMed, And Field Trip Health Headline PSYC's First CEO Round Table Event

Media company Global Trac Solutions, Inc. (OTCP:PSYC) and authorities behind psychedelic news and information platform Psychedelic Spotlight, announced that Psychedelic Spotlight will host its first “CEO Roundtable” on Feb. 15.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Psyched: UK Streamlines MDMA Therapy, FDA OKs MindMed's First LSD Trial In 40 years, Atai Launches Subsidiary

The Week In Psychedelics

Benzinga

MindMed Shares Soar After FDA Approves First Commercial Clinical Trial On LSD In 40 Years

MindMed (NASDAQ: MNMD), a drug development company in the psychedelics space, announced on Tuesday that the FDA has allowed an investigational new drug application for a Phase 2b trial on a proprietary LSD analog.

Benzinga

MindMed Successfully Completes Phase 1 Trial Of 18-MC

This article was originally published on Microdose and appears here with permission.

Benzinga

MindMed Launches Study Using Monitoring System For Psychedelic Experiences

Psychedelics biotech company MindMed (NASDAQ: MNMD) has enrolled the first subjects into its Session Monitoring System study. The company’s Session Monitoring System is a technology platform that can collect sensory data during a therapy session with a psychedelic drug.

Get all your
news in one place.

100's of premium titles.
One news app.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Ohio State University

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.